ATLANTA, March 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (the "Company"), an Atlanta-based, biopharmaceutical company, today announced that it intends to file a registration statement for the sale of $20.0 million or more of its common stock. The offering may also include shares to be sold by selling stockholders, although no arrangements have been made. The purpose of the offering would be to raise funds to enable the Company to develop its vaccines business.
This press release is being issued in accordance with Rule 135 of the Securities Act of 1933, as amended. THIS PRESS RELEASE IS NEITHER AN OFFER TO SELL NOR A SOLICITATION OF OFFERS TO PURCHASE COMMON STOCK. A REGISTRATION STATEMENT RELATING TO THE COMMON STOCK OF THE COMPANY HAS NOT YET BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. THE OFFER, IF COMMENCED, WILL BE MADE ONLY BY THE PROSPECTUS TO BE INCLUDED IN THE REGISTRATION STATEMENT
CONTACT: Robert McNally of GeoVax Labs, Inc., +1-678-384-7220,
rmcnally@geovax.com; or Leslie Loyet, Investor Relations, +1-312-640-6672,
lloyet@mww.com, or Nikki Snodgrass, Media Relations, +1-312-640-6732,
nsnodgrass@mww.com, both of Financial Relations Board, for GeoVax Labs,
Inc.
Web site: http://www.geovax.com/